According to FutureWise analysis, the GI stool testing market in 2025 is US$1.10 billion, and is expected to reach US$1.83 billion by 2033 at a CAGR of 6.57%. The gastrointestinal (GI) stool testing market is experiencing steady growth due to the increasing prevalence of gastrointestinal disorders, such as colorectal cancer and inflammatory bowel disease (IBD), as well as infections like C. difficile. This expansion is driven by a rising incidence of these disorders, greater awareness regarding early disease detection, and advancements in diagnostic testing technologies. Additionally, an aging population and a growing preference for non-invasive diagnostic methods are further contributing to market growth. GI stool testing involves analyzing stool samples to diagnose intestinal infections or diseases. Common gastrointestinal disorders include bowel inflammation, malabsorption issues, and cancer. The market is being propelled by the rise in GI diseases, attributed to unhealthy eating habits, busy lifestyles, and an aging demographic, which is increasingly susceptible to gastrointestinal infections. Both public and private sectors are expected to enhance investments in healthcare, further fueling market growth.There is a significant shift towards non-invasive testing, with an emphasis on home-based testing kits and point-of-care diagnostics, improving patient compliance and accessibility. The bacterial pathogen detection segment is anticipated to hold the largest market share in 2024, due to the high prevalence of bacterial infections and the availability of advanced diagnostic tests for their detection.Many studies have demonstrated a link between gut health and overall health. The gut microbiota specifically mediates the effects of nutrition and other factors on health, influencing digestive, immune, metabolic, and neuroendocrine processes. By employing appropriate methods to assess GI health, practitioners can identify the underlying causes of chronic illnesses. For instance, stool DNA tests, commonly referred to as FIT-DNA tests, detect traces of DNA (genetic material) released by polyps or colon cancers, rather than simply looking for blood. The Cologuard test is a popular screening tool of this type, as it can identify blood in stool samples and detect ten other factors associated with colon cancer.

Recent developments in the GI stool testing market include the launch of ColoClear by Circle (ColoClear) in June 2022 by Prenetics Group Limited, a global leader in genomic and diagnostic testing. This innovative, non-invasive, at-home screening test is designed to detect early signs of colorectal cancer and was introduced in Hong Kong.

FutureWise Market Research has instantiated a report that provides an intricate analysis of GI Stool Testing Market trends that shall affect the overall market growth.

Request a Free Sample @

https://www.futurewiseresearch.com/contact.aspx?rpt=3640&type=requestsample

By Product Type

• Reagents
• Instruments

By Application

• Colorectal Cancer
• Diarrhea
• GI Tract Infections
• Others (Poor Absorption Problems, Parasites)

By Test

• Microscopy Test
• Ova & Parasites Test
• Culture Test
• Bacteria Test
• Occult Blood test
• Guaiac FOB Stool Test
• Immuno-FOB agglutination test
• Lateral Flow Immuno-FOB Test
• Immuno-FOB ELISA Test
• Stool Biomarkers Tests
• Cologuard
• M2-PK Stool Test
• Others

By End User

• Hospitals
• Diagnostic Centres and Laboratories
• Academic Institutions
• Research Centres & Organizations
• Home Wholesale

• • Retail (in-store)
  • Distributors/ Franchises

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape in GI Stool Testing Market:

• Abbott Laboratories 
• Alere 
• Beckman Coulter 
• BioMrieux
• Bio-Rad Laboratories 
• Cenogenics Corporation 
• DiaSorin 
• Meridian Bioscience
• Quest Diagnostics Incorporated
• Siemens Healthcare 

Recent developments by key players in the GI Stool Testing Market:

BioMrieux

• Developed widely used VIDAS assays for detecting Clostridium difficile, including GDH antigen and toxins A/B, in stool-based infection diagnostics.
• In early February 2025, laboratories announced that the long-standing recall of BioFire GI panel kits was officially lifted after updated instructions for use (IFU) were distributed, restoring confidence in the platform.

DiaSorin

• Provides the LIAISON Calprotectin assay (CLIA-based) for non-invasive IBD screening, as well as elastase-1 and H. pylori stool antigen/antibody tests, which enable key differentiation in gastrointestinal diagnostics.
• Strategic partnerships, historically with Beckman Coulter and Meridian, continue to enhance GI infection and inflammatory biomarker testing portfolios; however, no new GI-specific assay launches were publicly announced for 2024 or 2025.

Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=3640&license=multi

**Objectives of this Study: **

1. To provide a comprehensive analysis of the GI Stool Testing Market By Product Type, By Application, By Test, By End User and By Region.
2. To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
3. To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
4. To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

                                                                                                                
Flexible Delivery Model:

• We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
• The customization services offered are free of charge with the purchase of any license of the report.
• You can directly share your requirements/changes to the current table of contents to: sales@futurewiseresearch.com